Serge Gauthier

TL;DR: The majority of patients treated with rivastigmine experienced improvements in attention, anxiety, apathy and agitation, and these real‐life findings further demonstrate the proven efficacy of rivASTigmine in patients with mild‐to‐moderate AD.

TL;DR: The PREVENT-AD dataset as discussed by the authors is an open science dataset from the Canadian Open Neuroscience Platform, which contains up to five years of longitudinal imaging data, cerebral fluid biochemistry, neurosensory capacities, cognitive, genetic, and medical information, and most of the other information, sensitive by nature, is accessible by qualified researchers at https://registeredpreventad.loris.ca.

TL;DR: Evidence is provided of frontal cortical involvement of tau pathology in behavioral/dysexecutive AD and the need for consensus clinical criteria in this syndrome is highlighted.

TL;DR: The relationship between retinal image features and β‐amyloid burden in the brain is investigated with the aim of developing a noninvasive method to predict the deposition of Aβ in thebrain of patients with Alzheimer's disease.

TL;DR: It is demonstrated that a considerable proportion of rivastigmine-treated patients experience improvements on each of the six symptoms studied, adding further support to previous randomised, clinical studies showing benefit of rivetigmine in AD.